Revelation Biosciences, Inc.
REVBNASDAQHealthcare● Active
$1.03
+$0.02(+1.49%)
Market Cap$4006130
P/E Ratio—
52W High$12.88
52W Low$0.875
Revelation Biosciences, Inc. (REVB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
REVB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$2.71
Est. -$1.15 · -135.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
REVB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 7, 2026 | -$0.83 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$1.15 | -$2.71 | -135.7% | — | — | — |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$3.66 | -$1.65 | +54.9% | — | — | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$5.36 | -$7.08 | -32.1% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$4.46 | -$7.01 | -57.2% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$20.64 | -$6.33 | +69.3% | — | — | — |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$9.60 | -$14.94 | -55.6% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 8, 2024 | -$136.33 | -$40.32 | +70.4% | — | — | — |
Q3 FY2026
Aug 7, 2026
EPS Actual
—
EPS Est.
-$0.83
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$2.71
EPS Est.
-$1.15
EPS Surpr.
-135.7%
Revenue
—
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$1.65
EPS Est.
-$3.66
EPS Surpr.
+54.9%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$7.08
EPS Est.
-$5.36
EPS Surpr.
-32.1%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$7.01
EPS Est.
-$4.46
EPS Surpr.
-57.2%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$6.33
EPS Est.
-$20.64
EPS Surpr.
+69.3%
Revenue
—
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$14.94
EPS Est.
-$9.60
EPS Surpr.
-55.6%
Revenue
$0.00B
Q4 FY2024
Nov 8, 2024Beat
EPS Actual
-$40.32
EPS Est.
-$136.33
EPS Surpr.
+70.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.79 | $-0.79 | $-0.79 | 1 |
| Q3 FY2026 | $-0.82 | $-0.81 | $-0.78 | 2 |
| Q2 FY2026 | $-0.88 | $-0.83 | $-0.78 | 2 |
| Q1 FY2026 | $-3.65 | $-2.71 | $-1.77 | 2 |
| Q4 FY2025 | $-3.89 | $-3.66 | $-3.43 | 2 |
| Q3 FY2025 | $-6.46 | $-5.34 | $-4.18 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -135.7% | $1.02 | $1.02 | +0.00% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +54.9% | $1.41 | $1.33 | -5.67% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -32.1% | $4.32 | $4.04 | -6.48% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -57.2% | $10.00 | $10.20 | +2.00% |
| ▲ Q2 FY2025 | May 8, 2025 | +69.3% | $34.76 | $37.16 | +6.90% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -55.6% | $42.36 | $41.52 | -1.98% |
| ▲ Q4 FY2024 | Nov 8, 2024 | +70.4% | $163.20 | $157.44 | -3.53% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +14.9% | $201.60 | $192.00 | -4.76% |
Q2 FY2026+0.00%
Report Date
May 7, 2026
EPS Beat/Miss
-135.7%
Price Before
$1.02
Price After
$1.02
Q1 FY2026-5.67%
Report Date
Feb 26, 2026
EPS Beat/Miss
+54.9%
Price Before
$1.41
Price After
$1.33
Q4 FY2025-6.48%
Report Date
Nov 6, 2025
EPS Beat/Miss
-32.1%
Price Before
$4.32
Price After
$4.04
Q3 FY2025+2.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
-57.2%
Price Before
$10.00
Price After
$10.20
Q2 FY2025+6.90%
Report Date
May 8, 2025
EPS Beat/Miss
+69.3%
Price Before
$34.76
Price After
$37.16
Q1 FY2025-1.98%
Report Date
Mar 6, 2025
EPS Beat/Miss
-55.6%
Price Before
$42.36
Price After
$41.52
Q4 FY2024-3.53%
Report Date
Nov 8, 2024
EPS Beat/Miss
+70.4%
Price Before
$163.20
Price After
$157.44
Q3 FY2024-4.76%
Report Date
Aug 9, 2024
EPS Beat/Miss
+14.9%
Price Before
$201.60
Price After
$192.00
Avg Beat Reaction-1.76%
Avg Miss Reaction-1.62%
Beat Rate4 / 8 quarters
Largest Move+6.90% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: REVB ends December
Revelation Biosciences, Inc. (REVB) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-2.71 — missing the analyst consensus of $-1.15 by -135.7%. The next REVB earnings date is expected around September 1, 2026.
Each quarter, investors track REVB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. REVB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
REVB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
REVB earnings · 5 questionsRevelation Biosciences, Inc.'s next earnings report is expected around September 1, 2026. REVB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; REVB historically reports after market close (AMC).
REVB earnings datewhen is REVB earningsREVB next earnings datewhen does REVB report earningsREVB earnings calendar
▸ Source: FMP · Revelation Biosciences, Inc. SEC filings · US GAAP · Revelation Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026